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Abstract
The field of environmental public health is at an important crossroad. Our current biomonitoring 
efforts document widespread exposure to a host of chemicals for which toxicity information is 
lacking. At the same time, advances in the fields of genomics, proteomics, metabolomics, genetics 
and epigenetics are yielding volumes of data at a rapid pace. Our ability to detect chemicals in 
biological and environmental media has far outpaced our ability to interpret their health relevance, 
and as a result, the environmental risk paradigm, in its current state, is antiquated and ill-equipped 
to make the best use of these new data. In light of new scientific developments and the pressing 
need to characterize the public health burdens of chemicals, it is imperative to reinvigorate the use 
of environmental epidemiology in chemical risk assessment. Two case studies of chemical 
assessments from the Environmental Protection Agency Integrated Risk Information System 
database are presented to illustrate opportunities where epidemiologic data could have been used 
in place of experimental animal data in dose-response assessment, or where different approaches, 
techniques, or studies could have been employed to better utilize existing epidemiologic evidence. 
Based on the case studies and what can be learned from recent scientific advances and improved 
approaches to utilizing human data for dose-response estimation, recommendations are provided 
for the disciplines of epidemiology and risk assessment for enhancing the role of epidemiologic 
data in hazard identification and dose-response assessment.
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INTRODUCTION
The field of environmental public health science is at an important crossroad. Advances in 
the interrelated disciplines it encompasses hold promise for our most comprehensive 
understanding of the influence of environmental stressors on human health to date. 
Estimates of the number of chemicals in commerce range from the tens of thousands to over 
140,000 [1]; the majority of these are still lacking any sort of toxicological evaluation 
necessary to set regulatory standards aimed at protecting public health [2, 3]. At the same 
time, advances in the fields of genomics, proteomics, metabolomics, genetics and 
epigenetics are yielding volumes of data at a rapid pace [4]. Our ability to detect chemicals 
in biological and environmental media has far outpaced our ability to interpret their health 
relevance [5]. Our increasing recognition of the joint behavior of multiple stressors (often 
those of varying nature) offers challenges to the traditional Hill Criteria-based approach and 
overemphasis on causation in toxicological assessment [6]. The environmental risk 
paradigm, in its current state, is antiquated and ill-equipped to make the best use of these 
new data that are being generated in a high-throughput fashion [7]. In light of these new 
scientific developments and the ongoing and pressing need to characterize the public health 
impacts and burdens of chemicals, we need to reinvigorate the use of environmental 
epidemiology in chemical risk assessment.
The purpose of this paper is to highlight opportunities and approaches that allow for the 
enhanced incorporation of epidemiologic data in risk assessment. We present case studies of 
chemical assessments from the Environmental Protection Agency (EPA) Integrated Risk 
Information System (IRIS) database to illustrate opportunities where epidemiologic data 
could have been used in place of experimental animal data in dose-response assessment, or 
where different approaches, techniques, or studies could have been employed to better utilize 
existing epidemiologic evidence. Based on the case studies and what can be learned from 
recent scientific advances and improved approaches to utilizing human data for dose-
response estimation, we make recommendations for the disciplines of epidemiology and risk 
assessment for enhancing the role of epidemiologic data in hazard identification and dose-
response assessment.
EPIDEMIOLOGY IN RISK ASSESSMENT
Environmental risk assessment, as a policy-driven framework established to facilitate use 
and consideration of scientific information in the decision-making process, is reliant on 
information from studies of the adverse effects of chemicals in living organisms. The 
process of quantifying the relationship between chemical exposures and health consequences 
in humans, known as dose-response assessment, is informed by data from studies of human 
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exposures to chemicals and studies in experimental animals, and can be supplemented by in 
vitro assays.
Historically, epidemiology has played the leading role in characterizing risks from agents 
with limited numbers of sources that are attributable to relatively greater morbidity and 
mortality, such as smoking. In contrast, risks resulting from multi-pathway lower level 
exposures to environmental chemicals have often relied on experimental animal data for 
toxicity characterization. Experimental animal data, as a function of laboratory-controlled 
settings, facilitate estimation of quantitative dose-response relationships and allow for the 
examination of the full range of toxic effects. As compared to epidemiologic studies, which 
usually are forced to rely on observational data [8, 9], animal studies are often considered to 
be better suited to evaluate effects for susceptible lifestages. Further, associations between 
exposure and effect estimated in human observational studies are subject to exposure and 
outcome misclassification due to frequent absence of direct exposure and outcome 
measurements and subsequent reliance on surrogate data; as a result of these often non-
differential biases, estimations of the strength of these associations likely result in 
underestimation [9].
The utility of animal studies in estimating dose-response relationships in humans has 
limitations. In particular, animal studies often require extrapolations (often from high to 
environmentally-relevant doses, and from shorter- to longer-term exposure durations) and 
applications of assumptions regarding similarities in toxicokinetics and dynamics across 
species [10]. In addition, while the controlled environment of animal studies may be useful 
in moving towards identifying causal relationships, studies of exposures in humans are better 
suited for evaluating exposures to mixtures and interactions among different classes of 
agents, direct evaluation of chemical exposures at environmentally-relevant levels, and 
characterization of actual human disease states.
Numerous advantages afforded by epidemiologic studies relative to those conducted in 
experimental animals have been identified (see Table 1) [11]. Use of human data in dose-
response estimation obviates or minimizes the impact of uncertainties that arise from certain 
necessary extrapolations inherent in using animal data, and it has been argued that 
uncertainties derived from exposure misclassification in epidemiologic studies are dwarfed 
by those stemming from potential interspecies differences [12]. Further, while high-to-low 
dose extrapolation may still be necessary in utilization of epidemiologic data (when 
extrapolating from occupational exposures to those in the general population, for example), 
the magnitude of such an extrapolation is often substantially reduced relative to 
experimental animal studies, coupled with a limiting of the associated uncertainty.
While subject to its own concerns, exposure assessment as conducted in epidemiologic 
studies may more accurately reflect the temporal nature (and delivery mechanism) of 
exposure as compared to experimental animal studies, and epidemiologic studies incorporate 
the true range of population exposures. Exposures to environmental contaminants rarely 
occur at a consistent rate and dose magnitude; in reality, exposures to environmental 
chemicals can be intermittent and at inconsistent doses. As a result, the careful, controlled 
administration of chemicals in laboratory animal studies creates an artificial dose regime that 
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may poorly approximate the true nature of exposure. Further, studies in experimental 
animals rely on a genetically similar strain, often of a single gender and lifestage, providing 
a limited context in which inter-individual variability or heterogeneity in susceptibility can 
be assessed [11, 13]. In addition, efforts to maintain an unchanging diet and consistent state 
of good health for experimental animals (in the absence of the substance being evaluated) 
results in a scenario that bears little semblance to that induced by real-world complexities 
that accompany human exposure [13]. Molecular epidemiologic methods, which employ 
biologic markers of early biological effect and susceptibility (such as genetic polymorphism 
data), allow for enhanced sensitivity and human relevance as compared to findings from 
studies in experimental animals [14, 15]. For these reasons, epidemiologic data may present 
opportunities not afforded by the experimental setting.
Despite potential advantages afforded by epidemiologic data in assessing dose-response 
relationships, numerous challenges have repeatedly been highlighted that argue against its 
use [11, 16], and a reluctance on the part of epidemiologists to participate in the risk 
assessment process [17] or tailor the reporting of their results for use in risk assessment has 
been noted [16, 18]. Prominent among these criticisms are issues regarding the sensitivity of 
epidemiologic methods, limitations of exposure measurements and the potential for 
confounding and other biases [11]. Further, challenges inherent in interpretation of the 
results of epidemiologic research may further inhibit its incorporation. Inconclusive results, 
poor documentation of methods and results, study design flaws, or positive findings in the 
face of considerable uncertainty may limit the utility of these data in quantification of 
relationships.
Additional challenges to incorporating epidemiologic data into risk assessment may arise 
from inherent differences in needed outputs between epidemiologists and risk assessors. In 
epidemiologic studies, information on dose is sparse, and in many cases, individual-level 
exposure data may be unavailable and estimation may rely on area-level or categorical 
assignments. It is often the case that these exposure and dose surrogates, as employed in 
epidemiologic studies, cannot be used in efforts to characterize quantitative dose-response 
relationships for individual chemicals, a critical component of risk assessment [16].
Risk assessments are frequently conducted and communicated to support a decision-making 
process, often occurring in the regulatory or standard-setting context and on a shorter time 
scale. On the other hand, the conduct of epidemiologic research is typically not driven by 
immediate regulatory or management need [16]. To this end, there exists inconsistency in the 
metrics utilized by epidemiologists and risk assessors to characterize dose-response 
relationships, particularly for noncancer health endpoints. The results of observational 
studies are typically presented in the form of odds ratios (ORs) or relative risks (RRs) 
associated with some increase in exposure, whereas reference values utilized in noncancer 
risk assessments have historically attempted to identify a dose threshold below which 
exposures are not likely to elicit adverse health consequences.
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SCIENTIFIC ADVANCES AND DEVELOPMENTS
Much attention has been lent to scientific advances that have occurred over the last decade 
and hold promise for improving the value of epidemiologic studies in the elucidation of 
dose-response relationships. Among these are the improved understanding and use of 
biological markers, wider acceptance of the concept of toxicity pathways and the 
significance of early biological perturbations, and potential applications of genomics, 
proteomics and metabolomics in support of chemical prioritization and dose-response 
assessment. In addition to these advances, evolving perspectives on issues critical to dose-
response assessment, such as variability in human susceptibility to chemical exposures as 
influenced by genetic and epigenetic factors, provide additional insight into the value of 
epidemiologic data in risk assessment. These advances, and their promise for enhancing the 
role of epidemiology in risk assessment, are discussed below.
Biomonitoring
The NRC defines biomonitoring as “one method for assessing human exposures to 
chemicals by measuring chemicals or their metabolites in human tissues or specimens” [5]. 
While biomarkers exist that serve as essential measures of chemical exposure, the same 
concept can be applied to evaluate chemical compounds in tissues as indicators of effect or 
susceptibility [19].
The rapidly expanding volume of biomonitoring data is changing the environmental 
epidemiologic landscape by improving our ability to evaluate exposures and outcomes and is 
becoming a critical component of modern epidemiologic investigations [20], involving 
measurement of chemicals or their metabolites in biological matrices at lower concentrations 
than those typically employed in experimental animal toxicological or human clinical 
studies [21]. This affords epidemiologists the ability to investigate changes that may occur at 
environmentally-relevant exposure concentrations [22] and, in many cases, allows for 
improved precision in characterization of exposure. In addition, biological markers of 
outcome and susceptibility allow for the ascertainment of frequency of subtle, subclinical 
toxicodynamic processes or the occurrence of unique vulnerabilities. Attention to these early 
changes and special populations will bolster the effectiveness of epidemiologic studies in 
steering the risk assessment process to provide the best possible characterization of the true 
nature of dose-response relationships, based on available data. Biomonitoring evaluations 
also hold promise for prioritizing epidemiologic studies [23], by highlighting gaps in 
toxicological knowledge corresponding to ubiquitous population exposures, as has been 
demonstrated in the case of polybrominated and polyfluoroalkyl compounds [24, 25]. 
Additionally, data collected in large-scale biomonitoring investigations can be useful in 
setting reference ranges to assist in exposure classification in epidemiologic studies [26, 27]. 
While the ongoing development of biomarkers holds promise for enhancing environmental 
epidemiology, biomarker development can be challenging [28]; to this end, efforts to 
identify the ideal characteristics for new biomarkers have been made [5, 29].
A number of domestic and international large-scale biomonitoring initiatives are either 
proposed, currently underway, or completed [30]. In the US, the National Health and 
Nutrition Examination Survey (NHANES), as conducted by the CDC and the National 
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Human Exposure Assessment Survey (NHEXAS), as conducted by EPA constitute the 
largest nationally-representative single-agency biomonitoring efforts, and a number of state-
based biomonitoring initiatives are underway [31]. The National Children’s Study (NCS), a 
longitudinal study aiming to evaluate the influence of environmental factors on health and 
development, will recruit 100,000 participants and encompass fourteen data collection 
events from parental pre-conception to the child between sixteen and twenty years of age. A 
number of biological specimens will be collected from the parents and the children [32]. 
Internationally, the European Commission, as part of the European Environment and Health 
Action Plan 2004–2010, has called for a Unionwide coordinated approach to biomonitoring 
in member states [33].
In its 2006 report, the NRC Committee on Human Biomonitoring for Environmental 
Toxicants noted that while population-based biomonitoring initiatives such as NHANES and 
NHEXAS are in place, and while advances in the laboratory have afforded us the ability to 
measure chemicals in tissues and other biological samples, there are relatively few chemicals 
for which methods for evaluating and interpreting the public health significance of these 
biological markers of exposure are in place [5]. The Committee recommended enhancing the 
use of biomonitoring data as it relates to risk assessment by calling for a coordinated 
strategy for biomarker development and continued population biomonitoring, prioritized on 
the basis of potential for exposure and public health concerns. The Committee also 
highlighted the current shortcoming of most large-scale biomonitoring efforts to collect data 
on important uniquely susceptible subpopulations; infants and children are often omitted 
from biomonitoring studies due to challenges related to sample collection. Further, a number 
of unique ethical issues pertaining to conducting biomonitoring studies in children have been 
identified [34]. While these difficulties in data collection may be viewed as prohibitory, 
information regarding exposure and susceptibility during earlier lifestages is essential in 
determination of critical exposure windows for young children. The development of new 
biomonitoring-based investigations as well as the enhancement of existing studies with 
biomonitoring components, both in experimental animals and humans, were recommended 
by the Committee [5].
Susceptibility
Inter-individual variability in susceptibility in response to chemical exposure, as mediated by 
age, disease status and a variety of other factors, has recently been highlighted as a critical 
consideration in dose-response assessment, particularly for elucidating the shape of the 
lower portion of the dose response curve. There has been increasing scrutiny of the adequacy 
of a threshold-based approach for noncancer effects; one perspective that has been presented 
is that individuals may exhibit a true dose threshold below which a response will not occur, 
though these individuals may differ in a variety of factors that influence where such a 
threshold may occur. Population-based variability in these influences, including genetic, 
epigenetic and behavioral factors, as well as existing morbidities and co-exposures, may 
obscure the true shape of the dose response relationship at low, environmentally-relevant 
doses, even in the case of chemicals with identified MOAs that are inconsistent with 
stochastic processes for key events [35]. Consequently, the use of a threshold-based toxicity 
value as a means of risk management at the population level is often not an accurate 
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reflection of our scientific understanding of the dose-response relationship within the 
population.
Hattis has suggested that improvements in the precision of exposure assessment in 
environmental epidemiologic studies, coupled with evaluation of appropriately selected 
biological markers, will provide critical insight into the degree and nature of interindividual 
variability in susceptibility to chemical insult [36]. Hattis argues that epidemiologists can 
play a key role in discerning the relevance of interindividual variability in dose-response 
relationships by moving towards acknowledging mechanistically-relevant factors in their 
study designs. In particular, for evaluating variation in susceptibility to noncancer quantal 
endpoints, Hattis advocates for categorization of variability parameters into human factors 
that influence chemical uptake, pharmacokinetics and pharmacodynamics [13]. Discrete 
consideration of variability within these categories across the human population, while 
adding complexity to dose-response characterization, may improve the ability of risk 
assessments to provide adequate protection to those uniquely susceptible while improving 
overall precision in specification of the dose-response relationship.
The NRC has recently reaffirmed the importance of addressing susceptibility in dose-
response assessment and provided recommendations for formalizing its consideration in the 
risk assessment process [7]. The enhanced susceptibility at early ages has begun to be 
addressed in risk assessment, with EPA adopting new guidelines to address increased risk 
during childhood from exposure to mutagenic compounds [37], and the California 
Environmental Protection Agency adopting guidelines to incorporate an extra factor to 
account for increased sensitivity to all carcinogens prenatally and during childhood [38]. 
While these actions incorporate some features of early-life sensitivity, the NRC notes that 
there are still further steps that can be taken, particularly for EPA, including development of 
methods to account for prenatal and other noncarcinogen exposures. The NRC also 
cautioned against defaulting to an assumption of zero variability in susceptibility in the 
absence of evidence to the contrary [7]. Evaluation of variation in population susceptibility 
plays a prominent role in the unified approach for dose-response assessment proposed by the 
NRC, assisting both in dose-response model selection and in identifying susceptible 
subpopulations for further assessment [7].
Advances in ‘Omics
The NRC committee on Toxicity Testing and Assessment of Environmental Agents released 
a report in 2007, stressing the inadequate capacity of current toxicity testing methodologies, 
which primarily rely on in vivo studies in experimental animals, and calling for a strategy 
that enables the scientific community to generate comprehensive toxicological information 
at an increasing rate [39]. As part of the Committee’s vision, attention was placed on 
identification and mapping of toxicity pathways, or cellular response pathways that result in 
adverse health effects when perturbed [4]. The Committee emphasized focus on preventing 
these perturbations, rather than clinically-observable endpoints, as a more appropriate goal 
for risk assessment. The view of the Committee was that the most effective means of 
achieving this goal is the eventual replacement (or near-replacement) of animal studies with 
the use of in vitro and in silico models of cellular and molecular systems to evaluate 
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biologically-relevant perturbations, which would allow for higher throughput chemical 
evaluation.
While numerous challenges exist in facilitating such a paradigm shift, including the 
considerable burden of adequately characterizing the toxicodynamics of these toxicity 
pathways, improved in vitro and in silico methods may hold promise for identification of 
biomarkers of exposure, effect and susceptibility that will be useful in epidemiologic 
investigations [39]. To this end, numerous ‘Omics technologies have been introduced, 
focusing on various levels of biological molecules and configurations ranging from the 
sequence of DNA and alterations of expression of DNA, RNA transcription, and the 
synthesis of proteins and other small molecules; however, the use of these technologies in 
risk assessment to date has been limited [40]. The output of these assays also holds promise 
for identifying the potential for chemical interactions or target organ potentiation, as 
elucidation of chemicals capable of eliciting the same initial biological perturbation can aid 
in targeting evaluation of commonly occurring mixtures where risk assessment conducted 
using standard dose-response assumptions may not reflect our best understanding of the 
underlying science.
Interest in characterizing the influence of epigenetic factors on disease susceptibility has 
become increasingly prominent in recent years. The term epigenetics refers to changes in 
gene expression that occur in the absence of alteration of DNA sequence [41]. It is 
increasingly recognized that environmental stressors are capable of eliciting epigenetic 
alterations; three targets of susceptibility for epigenetic insult, transposable elements, 
promoter regions of housekeeping genes, and imprinting genes, have been identified as 
alterable by changes in methylation patterns [42]. These targets are believed to be most 
sensitive to insult during certain lifestages, such as gestation, neonatal development, puberty, 
and old age [42]. The consequences of alterations to the epigenome and subsequent 
modifications of gene expression can translate to phenotypic changes that may impact 
disease susceptibility, behavior, and survival [41]. Recognition of the epigenome’s influence 
on gene expression offers a new perspective on interactions between genetic and 
environmental factors in predicting susceptibility and likelihood of disease development 
[43]. In particular, the heritable nature of some environmentally-induced epigenetic 
alterations highlights the concern that early-life exposures to environmental chemicals may 
not only be concerning for the exposed later in life, but also for subsequent generations. 
Epigenetic alterations induced by some endocrine disrupting chemicals, such as vinclozolin 
(as demonstrated by Jirtle and Skinner), have been demonstrated to elicit transgenerational 
disease phenotypes leading to adverse health consequences [41]. A recent workshop held by 
the British Committee on Toxicology addressed the issue of use of transgenerational 
epigenetics in regulatory toxicity testing [44]. The Committee outlined suggestions and key 
questions for the regulatory community with regard to incorporation of epigenetics data in 
risk assessment. Prominent among these were a call for alternative methods to test the 
potential for transgenerational epigenetic effects that would obviate the need for testing as 
far as the F3 and F4 generations [44].
Increased recognition of the potential for chemicals to elicit toxicity through an epigenetic 
MOA will improve the ability of toxicity assessments to realize the role of epigenetic 
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changes in the context of disease development [45]. Consideration of epigenetic alterations 
as markers of early biological perturbations along an effect continuum concluding with frank 
disease has the potential to improve the sensitivity of epidemiologic evaluations and may 
allow for identification of uniquely vulnerable subpopulations. Characterization of such 
markers may allow for the design of biomonitoring strategies that will generate data on 
epigenetic alterations in support of epidemiologic investigations.
Adversity and Recognition of Upstream Effects
Historically, risk assessments have relied largely on clinically-overt diseases or defects as 
measures of effect in dose-response estimation. In the context of derivation of noncancer 
toxicity values at EPA, these effects are referred to as “critical effects”, and are defined as 
“the first adverse effect, or its known precursor, that occurs to the most sensitive species as 
the dose rate of an agent increases” [46]. In contrast to its tendency to identify overt 
outcomes as critical effects, EPA defines an adverse effect as a “biochemical change, 
functional impairment, or pathologic lesion that affects the performance of the whole 
organism, or reduces an organism’s ability to respond to an additional environmental 
challenge” [47]. In an increasing number of cases, recent toxicological assays characterize 
early biological perturbations along the toxicodynamic continuum that precede frank effects; 
it is increasingly recognized that many of these initial perturbations, or upstream effects, are 
consistent with EPA’s current view of adversity. This will enhance the usefulness of 
epidemiology, because early biological markers can be more sensitive endpoints than more 
overt outcomes and are often measured on a continuous scale, so fewer observations are 
required to achieve sufficient statistical power.
The selection of critical endpoints in EPA risk assessments has been subject to criticism 
stemming from inconsistency with its definition of an adverse event. Debates about the 
significance of neurotoxicological endpoints highlight this confusion. Subtle perturbations 
that may influence deficits have frequently been dismissed for a number of reasons, 
including statistical imprecision in endpoint measurement instruments or population 
variability in a given neurological outcome masking a meaningful shift in a neurological 
parameter [48]. These shifts, while potentially viewed as insignificant for an individual, may 
have greater implications at the population level, where a slight shift in the population 
median value may result in a considerably larger number of persons within the range of 
adversity [49].
As provision of data regarding the doses at which these upstream effects occur becomes 
more routine, and as understanding of these early biological effects as adverse increases, 
there is mounting potential for these effects to be used as outcomes in risk assessments [50]. 
A scientific workshop was convened in 2007 to investigate the relationship between early 
biological changes and adversity. Participants identified three classes of early effects 
(thyroid perturbation, anti-androgen activity and immunological changes) where sufficient 
evidence exists to demonstrate linkage between these changes and observable disease, 
facilitating the direct use of these early biological changes in risk assessments. The 
recommendations of the workgroup also address consideration of factors that may influence 
the relationship between early biological markers and downstream effects, including 
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biological background, possible dose additivity or interaction, windows of susceptibility, the 
importance of multiple or complex modes of action, and impact of co-morbidities, unique 
susceptibilities and background chemical exposures [50]. Workshop participants emphasized 
that assessing risks for noncancer effects should move towards a non-threshold model.
Unified Approach to Dose-Response Assessment
The approach to noncancer dose-response assessment has been repeatedly criticized [7, 51–
53]. Noting the current dichotomy in methods for cancer and noncancer dose-response 
assessment, the NRC identified a goal of greater balance and coherence between the two by 
recommending use of information understood to influence individual and population dose-
response curves (such as mechanism of action (MOA), susceptibility, background exposures 
and others) to inform the model selection for characterization of dose-response relationship. 
This approach recommends the use of low-dose linear non-threshold model unless the basis 
for a threshold or non-linear relationship in the low dose range is clearly established. The 
NRC proposes a dose-response framework that redefines the RfD as a risk-specific dose, or 
a dose corresponding to a particular risk considered to be de minimis at a defined confidence 
interval, rather than as a “dichotomous risk - unappreciable risk descriptor” [7]. Such an 
approach could be used not only to derive the dose equated with a particular risk level but 
also to characterize risk at any dose. The NRC recommends that risk assessments for all 
endpoints be quantitatively-based and that a threshold should not be assumed for effects, 
instead recognizing the potential for continuous dose-response relationships in the 
population. [7].
The outputs from epidemiologic studies, when presented as ORs and RRs, provide the 
means to move towards non-threshold models and risk characterization metrics for non-
cancer endpoints because these measured differences in health outcomes can be readily 
converted to dose-response relationships. As opposed to being used to identify PODs from 
which bright lines can be identified, these epidemiologic outputs lend themselves to 
development of slope-based dose-response metrics. Bright line approaches to characterizing 
noncancer hazards are problematic, since a ‘safe/unsafe’ dichotomy does not speak to the 
probability or severity of health effects that occur at various points in the dose-response 
relationship [54].
EPA’S INTEGRATED RISK INFORMATION SYSTEM
The IRIS database is an online repository of toxicological evaluations of chemicals 
maintained by the National Center for Environmental Assessment at the EPA. It currently 
serves as the primary repository of risk assessments conducted by the EPA and its toxicity 
values are employed by entities at the international, national, state and local levels. Given its 
widespread use and recognition, toxicity assessments from the IRIS database will serve as 
case studies in this manuscript.
IRIS toxicological assessments encompass the hazard identification and dose-response 
assessment steps of the risk paradigm, as outlined by the National Research Council [7, 55]. 
Database entries for each chemical, depending on available evidence to support a 
relationship between exposure and effect, include the qualitative conclusions of a weight of 
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evidence discussion regarding a chemical’s carcinogenicity, quantitative estimates of 
carcinogenic potency (cancer slope factors [CSF] and inhalation and drinking water unit 
risks [IURs and DWURs]) and noncancer reference values (reference doses [RfDs] and 
concentrations [RfCs]). When attempting to characterize dose-response relationships at low, 
environmentally-relevant doses, IRIS assumes carcinogens to operate in a linear, non-
threshold fashion (except in the case of chloroform), whereas noncancer adverse effects are 
assumed to have dose thresholds below which these effects are unlikely. These toxicity 
values can be employed alongside site- or scenario-specific exposure data to estimate 
carcinogenic risk or potential noncancer hazard in exposed persons.
As of November 2009, the IRIS database contains evaluations of 553 chemicals. A recently 
published evaluation of the full IRIS database by EPA/NCEA scientists through June 2007 
found that human data was employed in the derivation of at least one chronic toxicity value 
for 44 chemicals (< 8% of all assessed) [56]. Of these, epidemiologic data directly supported 
the derivation of 27 RfDs (<8% of all RfDs), 12 RfCs (<16%), 3 CSFs (<4%) and 12 IURs 
(<22%). Based on this, while RfDs and CSF comprise more than 75% of all IRIS toxicity 
values, human data is more frequently employed in derivation of inhalation toxicity values. 
Potential explanations for the relatively higher use of human data in derivation of inhalation 
toxicity values could be that human observational studies employed in risk assessment often 
evaluate occupational (and non-dietary) exposures to air contaminants, and that the costs and 
ease of conducting oral exposure studies in experimental animals as compared to inhalation 
studies inadvertently result in the tendency for non-human toxicological evaluations to 
examine the oral route.
A subsequent inspection of assessments conducted since this evaluation did not reveal 
additional assessments using human data; the last assessment or update to employ 
epidemiologic data in the derivation of toxicity values was that for toluene, most recently 
revised in 2005. Further evaluation of use of human data in support of IRIS toxicological 
assessments over time reveals its limited application (<10%) prior to 1995, with an increase 
to its peak usage of 44% between 1995 and 1999, and again declining to support only 11% 
of critical effects in toxicological assessments conducted between 2005–2009 (see Fig. 1). 
Despite this, Persad and Cooper have noted that epidemiologic data are expected to play a 
more prominent role in assessments in preparation [56]. It should be noted that this limited 
inspection did not include an evaluation of the frequency of cases where epidemiologic data 
were available but were not used to support selection of a critical effect. Such an effort 
would be instructive in understanding the role of and identifying opportunities for 
epidemiologic data to play a role in future IRIS assessments.
METHODOLOGY/CASE STUDY APPROACH
To illustrate how epidemiologic data could be better integrated and utilized in risk 
assessment, we discuss two case studies of chemical assessments from the IRIS database. 
The IRIS Toxicological Review of Di-butyl Phthalate (External Review Draft) [57] was 
selected as an example of a case where toxicological data were used in derivation of toxicity 
values despite the availability of epidemiologic data. The IRIS Toxicological Review of 
Methylmercury [58] will be used as the second case study to demonstrate alternate 
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approaches for incorporation of epidemiologic data to facilitate toxicity value derivation. 
Within case studies, opportunities for incorporation of newer perspectives and the 
aforementioned shifts and advances in environmental public health science will be 
discussed. Following the case studies, recommendations will be provided for 
epidemiologists and risk assessors in pursuit of a more seamless translation of human data 
into guidance for decisionmakers.
CASE STUDIES – DI-BUTYL PHTHALATE
Background on Di-Butyl Phthalate
Di-butyl phthalate (DBP) is one of a number of phthalate esters used in the manufacture of 
consumer products such as cosmetics, drugs, personal care products and building materials. 
Phthalates are used as solvents, plasticizers, and emollients in these products. As 
constituents of consumer products and our physical environments, population exposure is 
common, as illustrated in recent biomonitoring surveys and research that demonstrates 
exposure to multiple phthalates in the US population [27, 59].
IRIS History and Health Effects of Concern—An oral RfD for DBP was first 
available in 1987, with the critical effect established as increased mortality based on a one-
year feeding study of rats [60]. A contractor for EPA reviewed and updated the assessment 
in 1990 (adding references and minor text edits), but no changes were made to the RfD [57, 
61]. In 2006, a revised draft toxicological review (TR) [57] was released and underwent 
external peer review. The 2006 Draft TR has not been finalized, and the IRISTrack system 
indicates that DBP is currently under re-assessment [62]. The next milestone listed is “Draft 
Development” – the first step of the IRIS review process - with an estimated due date of 4th 
quarter FY2010. Other phthalate esters are on the same timeline for draft development, 
suggesting a mixture approach is being considered, as recommended by the NRC Committee 
on the Health Effects of Phthalates [61]. It appears that EPA has moved quickly to undertake 
a new risk assessment that will incorporate multiple phthalates on the basis of population 
exposure to phthalate mixtures and common adverse outcomes observed in animals and 
humans. While the 2006 Draft TR is likely to differ substantially from the impending 
phthalates mixture assessment, it provides an opportunity to illustrate alternative approaches 
for using epidemiological data to develop risk-based toxicity values.
The noncancer health effects of primary concern identified in the TR (External Peer Review 
Draft) include reproductive performance, male reproductive development, histopathological 
changes in adult testis, and hepatic effects [57]. Male reproductive development was 
identified as the critical effect in the 2006 Draft TR.
The male reproductive malformations reported in toxicological evaluations of DBP include 
hypospadias; decreased anogenital distance (AGD); delayed preputial separation; agenesis of 
the prostate, epididymis, and vas deferens; degeneration of the seminiferous epithelium; 
nipple retention; gubernacular malformations and cryptorchidism [57]. The mechanism for 
many of the reproductive malformations has been identified as perturbation of androgen 
concentrations or androgen-receptor signaling [61]. Gubernacular malformations and 
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cryptorchidism are thought be to related to reduced insulin-like growth factor 3 (insl3) and 
reduced testosterone [61].
The constellation of fetal and adult male reproductive effects of in utero phthalate (DBP and 
others) exposures in animals described above has been termed “phthalate syndrome” [61, 
63]. The NRC [61] noted “excellent concordance” between the health effect data in animals 
and human “testicular dysgenesis syndrome” posited by Skakkebaek et al. [64]. 
Reproductive effects thought to have in utero origins in humans (e.g., infertility, decreased 
sperm count, cryptochordism, reproductive tract malformations, hypospadias, and testicular 
tumors) have been shown in rats exposed to phthalates in utero. Androgen insufficiency or 
disruption of androgen action underlies or contributes to all of these effects [61, 64]. The 
biological basis for the parallels between phthalate syndrome in animals and the 
hypothesized testicular dysgenesis syndrome in humans lies in our understanding of the 
specific requirement for androgen in normal male reproductive development in all mammals 
[61].
Overview of the 2006 Draft TR and RfD Derivation
Highlights of the DBP 2006 Draft TR are summarized in Table 2. Notable are the presence 
of both epidemiological and toxicological data, the large size of the toxicological database 
including multiple test species and multiple health effects; a good understanding of 
toxicokinetics in animals and some data for humans; and evidence in animals indicate that 
monobutyl phthalate is the toxic metabolite.
Critical evaluation of available data and scientific judgments on data quality and usability 
are inherent in the risk assessment process. Selecting the Lehmann et al. [65] rat study as 
basis for the point-of-departure was a significant scientific judgment made in the 2006 Draft 
TR.
The Lehmann et al. 2004 study was designed to investigate upstream or early biological 
effects, changes in gene and protein expression, and fetal testicular testosterone levels. Dams 
were exposed to DBP doses of ranging from 0.1, to 500 mg/kg-d in corn oil (by gavage) on 
gestational days 12–19. There were seven control animals and five animals in each dose 
group. Dose-dependent reductions in gene and protein expression and reduced testosterone 
in fetal testis were observed at dose levels below those shown to affect the developing 
reproductive tract. Lehmann et al. concluded that altered gene and protein expression and 
testosterone synthesis may be sensitive indicators of the testicular response to DBP [65].
In justifying the choice of an animal study, several limitations of the epidemiological 
literature were identified. Despite this, epidemiological data were cited as evidence 
supporting the main outcomes of concern (male reproductive development and function) but 
were not quantitatively applied in RfD derivation.
Concerns Related to the 2006 Draft TR
The RfD Derivation—One of the controversial decisions in the Draft TR was the 
definition of the no-observed-adverse-effect level (NOAEL) at the 30 mg/kg-d dose in 
Lehmann et al. 2004. This issue was raised by the National Resources Defense Council 
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(NRDC) in a presentation to the National Academy Committee on Health Risks of 
Phthalates in December 2007 [66]. The Draft TR authors cited difficulty in determination of 
the magnitude of hormone reduction that can be considered adverse (and were unsure of the 
biological significance of 26% hormone decrease at 30 mg/kg-d), and elected to rely on the 
statistical differences observed in hormone levels at the 50 mg/kg-d dose as the lowest-
observed-adverse-effect level (LOAEL). The lack of statistical significance observed in the 
30 mg/kg-d dose in the study was likely due to the small sample sizes employed in Lehmann 
et al., and a larger sample size would likely have yielded a significant difference. 
Accordingly, NRDC presented a position that the 26% decrease in fetal testicular 
testosterone at 30 mg/kg-d should instead be considered biologically significant and defined 
as a LOAEL. In this case, an additional LOAEL to NOAEL conversion factor would have 
been applied in RfD derivation, reducing the RfD by a factor of 10 (Table 3).
Epidemiological Data
Exposure Issues: The provision of information on phthalate mixture exposures is cited by 
the Draft TR as an impediment to use of those data for risk assessment. It can be argued that 
the epidemiologic data are more relevant for policy and preferred over the animal studies for 
the same reason.
The Draft TR reviewed four studies that found relationships between MBP (in urine or 
breast milk) and reduced sperm quality in adult men and AGI and reproductive hormones in 
infant boys (all of these studies examined and report exposures to multiple phthalate 
metabolites). MBP levels were reported differently in these studies. Duty et al. (2003a and 
2004) reported selected urinary percentiles including 25th%iles at 9.6 and 10.1 ng/ml and 
maximums at 488 ng/ml and 3169.9 ng/ml (not adjusted for specific gravity). The Main et 
al. (2005) study of reproductive hormones reported breast milk MBP minimums and 
maximums of 0.6 to 10,900 µg/L in the Denmark cohort and 2.4 to 123 µg/L in the Finnish 
cohort. Swan et al. (2005) provides observations similar to those found in the animal studies 
and reported 25th%ile urinary MBP at 7.4 ng/ml and a maximum of 337 ng/ml [67].
Marsee et al. used available pharmacokinetic models to back-calculate DBP exposure from 
urinary MBP levels presented in Swan et al. [67, 68]. They calculated daily median and 
95%ile DBP exposures of 1.00 µg/kg-d and 2.68 µg/kg-d, respectively. (The odds ratio for 
shorter than expected AGI at MBP levels above the 75th%ile was 10.2.) Using this 
information an epidemiology-based alternative RfD can be derived (Table 3). With no 
uncertainty factors (UFs) or adjustment for human variability applied, the Swan study data 
could result in an RfD of 0.001 mg-kg-d. Because effects on male infant development were 
observed in the Swan et al. study, it is likely that an additional UF adjustment for 
interindividual differences would be applied. As an example, considering various sources of 
human susceptibility as highlighted by the NRC [7] (up to 110 times more susceptible) an 
RfD of 0.00001 mg/kg-d could be calculated. If the Swan et al. study were used as the 
principal study for deriving an RfD, the likely value would fall within the range of values 
presented.
Alternatives 1 to 3 presented in Table 3 show RfD derivations (based on Lehmann et al. 
2004) that could result from differing scientific judgments regarding the data available at the 
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time of the Draft TR. These alternatives range from 0.1 mg/kg-d to 0.01 mg/kg-d. Using the 
Swan et al. and the Marsee et al. work, an epidemiology-based RfD can be derived that is 
one or more orders of magnitude less than what was proposed in the Draft TR or developed 
as examples here (ranging from 0.001 to 0.00001 mg/kg-d). The difference between the 
toxicology-based and epidemiologically-based RfDs could be because the epidemiologic 
data includes multiple exposures, which could lower the risk level, and/or due to increased 
biological sensitivity in humans compared to rats. For DBP, a risk assessment approach 
using epidemiologic data results in a substantially lower RfD than can be derived from 
animal data.
Study Design, Outcome Measures and Analyses—The Draft TR noted a particular 
concern about Swan et al. (2005), questioning the validity of AGI as an outcome measure for 
humans and raising doubt about the suitability of the study as a basis for risk assessment. At 
the time of the Draft TR there was only one other study of human males using this outcome 
[69], though human studies noting effects on sperm characteristics and postnatal 
reproductive hormone production added to the weight of evidence [70, 71]. The reliability of 
AGI was also questioned due to the challenge of controlling for differing age and growth at 
time of measurement.
Other limitations of the epidemiological studies were cited to justify the choice of the animal 
data, including the lack of causal data and methodological limitations; in particular, the 
Draft TR cited a lack of adjustment for possible confounders. Despite this claim, statistical 
modeling procedures in each of the recent studies did address selected confounders and 
known important covariates, including ethnicity, age (and gestational age), smoking status, 
and body mass index and other demographic factors [68, 70–74]. Citing the lack of causal 
data as justification for the animal data raises questions regarding evidence standards for 
regulatory risk assessment. What standard of evidence is appropriate? What are EPA’s data 
evaluation standards? The standards of evidence for policy making and specific examples of 
EPA guidance on data sufficiency are explored further below.
Standards of Data Sufficiency for Risk Assessment—EPA designs risk assessments 
to avoid underestimation and gross overestimation of risk and to ensure protection of public 
health and environment [75]. This approach to evaluation of scientific information differs 
from the higher bar set for standards of scientific proof.
Establishing proof within a scientific process has a very high standard of evidence to avoid 
false positives [6, 76]. In this way, scientific knowledge grows by an accumulation of the 
strongest evidence. In contrast, for risk assessments used in the regulatory policy arena the 
standard of evidence shifts. Regulatory processes are designed to establish health protective 
policies and a wide range of scientific data are evaluated in an effort to avoid false negatives 
[77]. It also allows for decision-making even when uncertainties remain in the science. As 
science is an evolving process, complete certainty is elusive, and requirements for certainty 
are not compatible with decision-making needs, which are often on a shorter time scale. 
Thus, having a likely concern is sufficient for taking preventive action in some areas (e.g., 
cancer).
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Data Sufficiency: The Case of DBP: The health effects stemming from DBP exposure can 
be categorized as reproductive and developmental, adding complexity to the selection of 
critical endpoint; in addition, the observed effects are linked by the overarching biological 
framework of phthalate syndrome/testicular dysgenesis. Further complicating matters are 
EPA’s guidance documents for risk assessments for developmental and reproductive toxins, 
which differ regarding evaluation of epidemiological data to establish “sufficient human 
evidence” in support of quantitative risk assessment.
The guidelines for risk assessment of reproductive toxins [78] have very stringent standards 
for “sufficient human evidence” (emphasis added):
“This category includes agents for which there is convincing evidence from 
epidemiologic studies (e.g., case control and cohort) to judge whether exposure is 
causally related to reproductive toxicity. A case series in conjunction with other 
supporting evidence also may be judged as Sufficient Evidence. An evaluation of 
epidemiologic and clinical case studies should discuss whether the observed effects 
can be considered biologically plausible in relation to chemical exposure. (EPA 
1996, page 72)”
In comparison, the guidelines for risk assessment of developmental toxins [79] have a less-
stringent data sufficiency standard for epidemiological data (emphasis added):
“Sufficient Human Evidence: This category includes data from epidemiologic 
studies (e.g., case control and cohort) that provide convincing evidence for the 
scientific community to judge that a causal relationship is or is not supported. A 
case series in conjunction with strong supporting evidence may also be used. 
Supporting animal data may or may not be available. (EPA 1991, page 40)”
The EPA 2005 Guidelines for Carcinogen Risk Assessment present an additional approach 
to data evaluation and applications of epidemiological data in risk assessment [80]. The 
cancer guidelines adopt data sufficiency standards for each descriptor used to characterize 
cancer hazards. The guidelines anticipate that combinations of animal, human and in vitro 
data and studies needed to support any particular descriptor may vary and can be used in 
concert to support the different weight of evidence descriptors. For example, the descriptor 
“carcinogenic to humans” can be based on convincing epidemiological evidence of a causal 
association, or in exceptional cases, for cases where a less robust epidemiological dataset is 
corroborated other lines of evidence from nonhuman studies. For the descriptor “likely to be 
carcinogenic in humans”, supporting evidence can include a wide range of study types and 
data, including plausible associations between human exposure and cancer; definitive causal 
data in humans is not required. “Likely to be carcinogenic in humans” is the most common 
descriptor and quantitative risk analyses are conducted for these agents. For dose-response 
assessment of carcinogens, the cancer risk guidelines state a preference for epidemiological 
data. Common limitations of epidemiological data are acknowledged as part of this process, 
and strategies for adjusting the data to derive epidemiologically-based CSFs or unit risks are 
provided.
Applying the Data Sufficiency Guidance to DBP: At the time of the Draft TR, an 
argument for using epidemiological data for the DBP RfD derivation could have been built 
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upon the guidelines for risk assessment for developmental toxics [79]. Two studies found 
developmental effects of reduced AGD and hormone changes [68, 71] and two others in 
adults found male reproductive effects [72, 73]. While the adult studies are technically 
considered reproductive rather than developmental, they still lend support to the 
developmental findings, as DBP is thought to affect a continuum of male reproductive health 
endpoints by interfering with androgens and other points along that pathway. This dataset 
includes case-control, cohort and cross-sectional study designs, strengthening the weight of 
this evidence. Given this diversity of studies, the epidemiologic dataset could stand alone as 
“convincing” evidence. Further, the toxicological evidence for DBP’s antiandrogenic activity 
and effects on AGD is also strong [81, 82]. Considering the epidemiological findings and 
their consistency with results from animal studies and the hypothesized toxic mechanism, 
the available data at the time of the Draft TR provided convincing evidence in favor of a 
causal relationship.
Under the guidelines for risk assessment of reproductive toxins, the research of Duty et al. 
[72–74] and Main et al. [71] would have been the foundations of the case for using the 
epidemiological data in derivation of the DBP RfD. In the work of Duty et al. there was one 
statistically significant study [73] and one study suggestive of a relationship between urinary 
MBP levels and reduced sperm motility [72]. Main et al. found statistically significant 
associations between MBP in breast milk and higher levels of sex-hormone binding globulin 
(p=0.01) and lower levels of free testosterone (p=0.03) in 3-month old infant boys [71]. The 
strengths of the epidemiological dataset regarding reproductive effects were the statistically-
significant findings in multiple studies of varied design showing effects on adult sperm 
parameters and infant hormone levels. The reproductive toxicity findings in humans were 
consistent with the toxicological findings and the proposed MOA. In sum, the totality of the 
epidemiological data in conjunction with the animal evidence provides a strong case that the 
human evidence was sufficient for the quantitative risk assessment of DBP.
The cancer guidelines present a more graded and contemporary discussion of data 
sufficiency that incorporates a pragmatic approach to data evaluation. They maximize the 
utility of epidemiological data with adjustments that account for common limitations, and as 
in previous guidance, advocate the consideration of the whole of the available literature 
(including human, animal and in vitro evidence). An argument for deriving the RfD on the 
basis of epidemiological data on male development or reproductive effects could be 
developed with the frameworks laid out in the cancer guidelines.
Epidemiological Data then and Now
Table 4 summarizes the epidemiological studies reviewed in the Draft TR as well as several 
important studies released after the publication of the Draft TR that have strengthened the 
evidence base for male reproductive effects in infants and adults [70, 83, 84]. These include 
further findings of an association between MBP and reduced sperm count and motility from 
continued evaluations of patients from male fertility clinics [72–74]; further expansion of the 
findings of the association with AGD from the Study for Future Families cohort [68], and a 
new finding of an association with behavioral differences in boys. In addition to further 
follow-up and new statistical analyses to address the reliability of the AGD measure, Swan 
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et al. [83] reviewed the evidence on AGD in humans to address concerns about the validity 
of the outcome.
Alternative Approaches Using the Epidemiological Data
As demonstrated by this case example, development of the RfD using epidemiologic data 
could take several forms, including: the RfD based on the Lehmann et al. could have been 
adjusted to reflect the differences in levels of exposure between Lehmann et al. and in the 
Swan et al. and Hauser et al. papers (with back-calculation of DBP exposure as 
demonstrated by Marsee et al); Swan et al. or Hauser et al. could have served as the critical 
study for identifying the POD and deriving the RfD (again with back-calculation of DBP 
exposure); or use of a statistical approach to develop the POD combining information from 
multiple human studies integrating different populations and endpoints. Basing the POD on 
the human data is the preferred approach as it eliminates the need for animal to human 
extrapolation and ensures that the assessment reflects realistic population settings and co-
exposures to other phthalates. An assessment using epidemiologic data would rely on the 
same foundations (strong toxicological dataset with described mechanisms of toxicity from 
animal studies, which are plausible in humans) as laid out in the Draft TR.
Considering the syndromic morbidity associated with DBP exposure, a third approach that 
allows combining data from multiple studies could be explored. With the addition of Swan 
et al. 2009 [84], the epidemiologic dataset includes four different outcomes, alternations in 
adult male sperm parameters related to the men’s urinary MBP levels, AGD in infant boys 
and less-masculine play behaviors in young boys related to prenatal DBP exposure as 
assessed by MBP in maternal urine samples, and postnatal reproductive hormone differences 
in boys associated with MBP in breast milk. It may be premature to pursue a data 
combination approach based on the existing DBP epidemiology; however, as the dataset 
grows, opportunities to use statistical methods to integrate findings from multiple studies 
may arise. Several methodologies are available including Bayesian approaches as described 
by Sutton and Abrams [85] or a composite score method as described by Coffey et al. [86] 
and illustrated by the NRC Committee on the Health Risks of Phthalates [61]. As with any 
new method, the utility and technical feasibility of a data combination approach would need 
to be evaluated carefully. Some approaches to data combination (e.g., Bayesian) will foster 
advances in dose-response modeling such as those recommended by NRC (2009) in the 
unified approach to dose-response.
Epidemiological Data Have Advantages But Many Challenges Persist
Use of epidemiologic data will eliminate the significant uncertainty stemming from 
interspecies extrapolation but will not eliminate numerous other uncertainties or obviate 
scientific judgments from risk assessment. For example, one of the challenges is 
characterizing the population-level implications of changes in continuous biological 
parameters, such as testosterone. Recent workshops have identified any shift in such 
parameters as adverse, but further work is needed to translate this into quantitative terms. 
Evaluation of certainty regarding important sources of human variability would need to be 
conducted to ensure accurate, science-based characterization of dose-response relationships 
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that account for uniquely-susceptible subpopulations. Uncertainties related to exposure, 
dose, and dose-response modeling must also be addressed.
Di-Butyl Phthalate Case Study Conclusions
The DBP example illustrates challenges and complexities encountered in cumulative risk 
analyses, including evaluation and incorporation of realistic population exposures to 
multiple chemicals, analyses of multiple endpoints and evaluation of multiple populations of 
concern. The use of DBP epidemiological data would have better addressed these challenges 
by improving accuracy in determination of the dose-response relationship, thus providing a 
stronger basis for risk assessment.
CASE STUDY - METHYLMERCURY
An extensive toxicological and epidemiological literature base for methylmercury (MeHg) 
enabled the EPA in 2001 to establish an RfD incorporating a number of risk assessment best 
practices [58]. Methylmercury is among the few chemicals for which the RfD is derived 
from studies of general population exposure, obviating the need for high- to low-dose 
extrapolations from occupational studies or cross-species extrapolations from animal data. 
Biomarkers of internal dose were employed to characterize MeHg exposure, likely reducing 
misclassification bias. The MeHg RfD was derived based on the benchmark dose (BMD) 
method, which is superior to the NOAEL/LOAEL approach as it uses all dose-response 
information [87]. The case study also illustrates the potential for the MeHg risk assessment 
to continue to evolve towards the unified dose-response and risk-specific dose framework set 
out in the new Science and Decisions risk assessment paradigm [7] and to incorporate 
additional, potentially more sensitive endpoints such as cardiovascular disease (CVD). It 
also highlights the fact that, despite this potential, no re-assessment of MeHg is currently 
planned by EPA [62].
Background
Mercury (Hg) is a ubiquitous heavy metal contaminating the global seafood supply. 
Elemental mercury vapor is released into the atmosphere by anthropogenic and natural 
events, deposited onto waterways, and converted to MeHg by aquatic microorganisms. 
Methylmercury bioaccumulates efficiently in fish tissue and biomagnifies up the food chain. 
About one-third of inorganic mercury (iHg) emissions is anthropogenically-generated, in 
large part through combustion of fossil fuels and industrial and waste management 
processes; another third is re-emission of human and natural emissions; and the remaining 
one-third is from natural processes such as volcanic eruptions; [88]. Elemental mercury 
vapor has a long half-life (up to a year) in the atmosphere, and therefore travels with 
meteorological systems and deposits globally [89]. The dominant pathway of seafood [90]. 
Mercury has been found in the tissues of all human populations, including those in the 
remotest parts of the world [91]. Detectable levels of Hg are found in the blood of over 90% 
of reproductive age women in the US [92].
Nachman et al. Page 19
Open Epidemiol J. Author manuscript; available in PMC 2019 July 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
IRIS History and Health Effect of Concern
Mercury affects multiple organ systems, though its effects on the central nervous system 
(CNS) are best studied. While Hg’s neurotoxicity has been known for centuries, major 
accidental poisoning events in Minamata, Japan in the 1950s (as a result of industrial-
effluent contamination of seafood) and in Iraq in the 1970s (due to fungicidal contamination 
of wheat used in bread) demonstrated MeHg’s differential neurotoxic effects in adults and 
children. Minamata was the first demonstration of infants with brain damage -- ranging from 
subtle development delays to mental retardation and cerebral palsy -- born to mothers who 
themselves suffered few or no adverse effects. Similar results were seen in Iraq, where dose-
response relationships suggested delayed walking could occur as at concentrations as low as 
10 ppm in maternal hair [93]. This suggested a much greater sensitivity of the developing 
fetus to MeHg’s neurotoxic effects.
The mechansim for MeHg neurotoxicity is complex and incompletely understood. MeHg 
crosses the blood-brain and placental barriers, providing one key explanation for enhanced 
fetal vulnerability. Autopsy studies have found that while adult exposures result in limited 
lesions in the brain, prenatal exposures produce widespread changes in the brain’s 
cytoarchitecture [93]. Several main MOAs have been suggested for CNS damage: (i) 
disrupted protein synthesis; (ii) cell structure damage; (iii) induction of lipid peroxidation 
and generation of reactive oxygen species (ROS); (iv) and interference with calcium 
homeostasis [93, 94].
The EPA’s chronic oral RfD for MeHg of 0.1 ug/kg/d was set in 1995 based on the 
poisoning episode in Iraq [58, 95]. The NAS, at the request of Congress, reviewed 
substantial then-available experimental and epidemiological evidence, concluded that 
“neurodevelopmental deficits are the most sensitive, well-documented effects”, and provided 
a recommendation for an RfD [90].
The epidemiological data included three large population-based cohort studies focusing on 
developmental neurotoxicity resulting from in utero exposure to MeHg-contaminated 
seafood in high fish-consuming communities in the Seychelles [96, 97], the Faroes Islands 
[98], and New Zealand [90]. Statistically-significant associations of mercury exposure 
biomarkers and a range of subtle neurological effects in children born to MeHg-exposed 
mothers were found in the Faroes and New Zealand studies, while no such clear 
relationships were found in the Seychelles study. The NRC committee chose the Faroes as 
the principal study due to its strengths. The lowest benchmark dose (BMD) considered 
reliable was for the Boston Naming Test from which it derived a lower confidence limit 
(BMDL05) of 58 ppb in cord blood, equivalent to about 12 ppm in hair (Table 5). The 
benchmark dose is the dose corresponding to a pre-selected change (often 5 or 10%) in 
response [99]. The committee identified biological variability in estimating dose and 
database insufficiency as the two major areas of uncertainty, and recommended an UF of 2 
to 3 for variability and an additional factor “given the data indicating possible long-term 
neurological effects not evident at childhood, immunotoxicity, and cardiovascular effects,” 
for a total of “at least 10” [90].
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Overview of the RfD
Broadly following the NRC’s recommendation, the EPA’s RfD was based on the Faroes 
study. While the RfD itself remained the same, the basis was adjusted to reflect newer 
epidemiological evidence in a chronic exposure setting more comparable with real life 
exposures in the general population. The EPA chose BMDLs of 46–79 ppb in maternal 
blood for several neurological test scores in the Faroes cohort, supported by an integrative 
analysis of the three studies [90], rather than relying on one test score [58]. An UF of ten 
was applied (three for toxicokinetic variability and three for toxicodynamic variability) to 
account for the inability to quantify long-term sequelae, the lack of a two-generation 
reproductive-effects assay, and issues related to selection of critical effect -- specifically, 
concern about the possibility of MeHg effects lower than the chosen BMDL [58]. Table 5 
shows a comparison of the NRC recommendations and the EPA RfD.
Evidence of effects on the cardiovascular system (at lower doses than those associated with 
neurological effects), delayed and lifespan neurotoxic effects, and immune and reproductive 
system effects was available at the time the RfD was established. However, as the NRC 
Committee concluded “on the basis of the body of evidence from human and animal studies 
… neurodevelopmental deficits are the most sensitive, well-documented effects and 
currently the most appropriate for derivation of the RfD.” Lack of completeness in the 
epidemiological knowledge base was explicitly built into UFs.
Moving Toward Unified Dose-Response Assessment
Bright line approaches to characterizing noncancer hazards are problematic (as noted 
above), since a ‘safe/unsafe’ dichotomy does not speak to the probability or severity of 
health effects that occur at various points in the dose-response relationship [54]. Using 
MeHg to illustrate, Clewell and Crump note that the difference in distributions of mean 
neurological test scores modeled in the NRC risk assessment between children of mothers 
who were exposed at the RfD compared with unexposed was a 0.25%, a change the authors 
describe as “barely discernable”. To characterize risk of developmental neurotoxicity at 
higher-end exposures, biomonitoring results from the NHANES 1999–2000 cross-sectional 
survey were employed, choosing the 99.8th percentile (second highest observed value) blood 
mercury level. Based on the modeled mean test score difference they found a decrease in 
mean test score of 1.6% in children born to mothers exposed at the 99.8th percentile 
compared with those born to unexposed mothers. Based on NHANES sampling, they report 
an estimated 8,000 births at risk annually (Table 6).
Axelrad et al. estimated a dose-response relationship by standardizing neurological test 
scores to the IQ scale and using a Bayesian model to perform an integrative re-assessment of 
the data from the three key MeHg epidemiologic studies [100]. For exposed children, they 
estimated a loss of 0.18 IQ point for each part per million (ppm) of mercury in maternal hair. 
Adapting the Clewell and Crump approach using the Axelrad et al. dose-response 
relationship suggests risk of loss of 0.82 IQ point at the 99.8th percentile of maternal 
exposure for the 8,000 annual births (Table 6). With a quantified dose-response relationship 
and distribution of internal dose for a representative sample of the population, similar 
estimates are possible for any percentile of the exposure distribution. In improving the 
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precision of estimated severity and frequency of risk, this type of characterization is likely to 
be more informative for risk management and communication, as well as benefit-cost 
assessment [54]. Stating that 8,000 children born annually to mothers at the highest 
percentile of MeHg exposure dose may be at risk of an approximately 2% lower 
performance on a standardized neurodevelopmental test, or a nearly 1-point loss in IQ, is 
likely to be more informative for decision-makers than stating that 60,000 births annually to 
mothers with intake over the RfD are at some unspecified level of risk [90]. These examples 
from recent publications offer insight into methodological refinements and are presented for 
illustration. The examples presented address only two of the many neurological effects of 
MeHg; the effects estimates above do not capture (and therefore underestimate) the full 
impact of MeHg exposure.
Building on such approaches, the NRC set out three conceptual models for calculation of a 
risk-specific dose, based on individual and population dose-response relationships [7]. 
Examination of MOA, background exposure and variability would guide choice of a dose-
response conceptual model. Epidemiological research will provide much of the basis for 
these assessments. Given observed individual low-dose linearity [90] and sufficient 
background exposure and variability to presume low-dose population linearity [7], MeHg is 
likely to fall into the category of the third conceptual model which extrapolates from the 
human point of departure linearly to low dose and then estimates population and individual 
risk and uncertainty based on inter-individual variability distributions [7].
To this end, research in the last ten years has contributed to reduced uncertainty in the 
relationship between mercury measured in newborn cord blood to that in maternal blood. In 
determination of the RfD, maternal intake doses were modeled from measured MeHg in 
fetal cord blood. While aware of data reflecting cord to maternal blood ratios substantially 
above one [101–103], EPA chose to use a ratio of one for this purpose representing the 
central tendency of this ratio. Interindividual variability of this ratio was included as a 
component of the toxicokinetic UF [58]. A meta-analysis of ten published studies found a 
ratio of 1.7 for cord to maternal blood mercury [104]; some researchers have interpreted this 
finding to mean the estimated internal dose equivalent of the RfD (5.8 ug/L in blood) should 
be adjusted downward by this ratio, and have reported blood levels of mercury using 3.5 
ug/L as a reference value [105, 106].
In a subsequent probabilistic assessment incorporating the 1.7 cord-to-maternal blood ratio 
and reconsidering key parameters of the NRC MeHg model, Stern derived a distribution of 
the intake needed to reach 58 ppb MeHg in hair, NRC’s POD [107]. For example, an 
estimated intake of 0.2 ug/kg/day would be sufficient to reach this level at the 1st (99th) 
percentile. The author argues that reducing uncertainty in cord-to-maternal blood and other 
model parameters substantially reduces the need for toxicokinetic UFs, although factors for 
database sufficiency and toxicodynamic variability would still be applied [107]. To illustrate, 
a factor 3-fold for toxicodynamic variability applied to the 1st (99th) percentile suggests an 
intake of 0.067 ug/kg/d, or two-thirds of the current RfD. This analysis moves in the 
direction of a risk-specific dose by reducing uncertainty in an important measure of inter-
individual variability and evaluating risk at a specific percentile of MeHg intake.
Nachman et al. Page 22
Open Epidemiol J. Author manuscript; available in PMC 2019 July 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Susceptibility factors are “broadly considered to include any factor that increases (or 
decreases) the response of an individual to a dose relative to a typical individual in the 
population” [7]. The NRC concluded that variability in human susceptibility had not been 
adequately considered in EPA risk assessments and recommended that more explicit 
evaluation of population variability should be incorporated in both exposure and dose-
response assessment. The RfD for MeHg is unusual in that it targets a specific group that is 
susceptible due to gender and lifestage; however, the population of reproductive-age women 
is large and heterogeneous, and substantial regional differences have been documented. 
While based on NHANES 1999–2004, on average 4.7% of reproductive age women were 
over the RfD, only 1.2% were over the level in the Midwest compared with 9.0% in the 
Northeast [106]. Similarly, 8.1% of the coastal population was over this limit compared with 
2.1% of non-coastal. A cross-sectional survey in New York City found 25% of women over 
the RfD equivalent, and nearly two-thirds of those of Asian origin over that level [108]. 
Blood mercury levels are strongly associated with seafood intake in these studies [106]. 
Even among NHANES seafood consumers in the same monthly frequency category 
substantial variability in internal dose exists, ranging from 4 to 8-fold [92].
Not all individuals in the population will respond the same way to a given exposure dose; 
genetics, lifestyle, co-exposures and other factors are likely to also play a role in chemical 
metabolism and elimination. In the case of MeHg, Castoldi et al. have raised the importance 
of diet (essential fatty acids, selenium, vitamin E), gender, temporal patterns of exposure, 
and co-exposure with other toxicants in potentially modifying the effects of MeHg on 
neurotoxicity throughout the lifespan [109]. Essential fatty acids in seafood, in particular 
eicosapentaenoic and docosahexaenoic acids, are important for brain function [110]. Studies 
have suggested essential fatty acids and MeHg may interact antagonistically with respect to 
neurotoxicity. Caution in epidemiological studies is warranted because unadjusted 
confounding from a beneficial moderating factor may lead to an underestimate of adverse 
effects [111]. Similarly, the need for examining nutrients, chemicals (particularly persistent 
organic pollutants), and the social environment for possible modification of MeHg 
neurotoxicity has been identified [112]. A recent re-analysis of the 9 year follow-up of the 
Seychelles cohort -- a study that found no consistent adverse effect associated with seafood-
related MeHg exposure -- concluded that motor function decreased significantly with MeHg 
exposure in children with a below-average home environment [113]. The NRC has identified 
that “the data gap represented by interhuman pharmacodynamic (PD) variability presents a 
critical research need that can be approached by mining the existing epidemiology literature 
and by designing new studies in which biomarkers of exposure and effect are used to 
describe variability in sensitivity to health outcomes in similarly exposed people.” Further 
development of such research will be important in determining risk-specific doses [7].
Multiple Endpoints and Data Sufficiency
Since the NRC mercury report, the scientific basis for MeHg’s adverse effects on multiple 
health endpoints has strengthened. In particular, substantial epidemiologic evidence of risk 
to the cardiovascular system at doses well below the BMD for developmental neurotoxicity 
has emerged.
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At the time of the NRC review, while the committee observed that “the cardiovascular 
system appears to be a target for MeHg toxicity… at very low Hg exposures,” only two large 
epidemiological studies had been conducted (Table 7). One found an association between 
MeHg exposure and acute coronary events in Finnish seafood-consuming men [114] and the 
second an association between MeHg and blood pressure and heart rate variability in Faroes 
Island children [115]. Over the last ten years at least 11 additional reports have been 
published (Table 7), summarizing findings from 10 primarily observational studies of MeHg 
exposure from seafood consumption in general populations of mostly men covering 16 
countries. These studies examine three sets of CVD-related outcomes: (i) acute coronary 
events (myocardial infarction, MI) and other heart disease events and risk markers, (ii) 
hypertension and (iii) heart rate variability. Most found positive associations between MeHg 
exposure and risk of CVD outcomes, particularly those examining adult male populations. 
The mean mercury level in the four published reports from the large Finnish KIHD cohort 
study (about 1.9 ppm in hair) is about six-fold lower than the BMD for developmental 
neurotoxicity for the EPA RfD. Thus, as early as 15 years ago, epidemiological evidence 
was available suggesting population health effects at levels substantially lower than the RfD. 
Given this, the issue of data sufficiency needed to spur action once again becomes critically 
important.
A 2005 review of the MeHg-CVD epidemiology found convincing evidence in support of an 
association between dietary MeHg exposure rates from fish and CVD endpoints in adult 
men, including MI [107]. This review further concluded that the Finnish KIDH cohort study 
provided the strongest basis for quantitative risk assessment of the cardiovascular effects of 
MeHg. Despite this, several concerns with the epidemiological and experimental bases for 
risk assessment were raised. First, while large and well-conducted case-control studies on 
men in the US [116], the EU and Israel [117] examining MI and other CVD risk parameters 
could provide the basis for risk assessment, these studies are based on a biomarker (toenail 
mercury) with a poorly studied relationship with MeHg intake. Second, mechanistic 
evidence for MeHg’s role in CVD remained weak, though oxidative stress was noted as a 
plausible mechanism. Finally, the evidence for hypertension was less conclusive than for 
CVD outcomes, and while heart rate variability was clearly a nervous system effect, its link 
to CVD risk was unclear [107].
Additional research conducted since the 2005 review has strengthened the case for 
cardiovascular endpoints in adult males. Over the last several years, associations between 
toenail mercury, hair and blood mercury and MeHg intake have been quantified [118], and 
toenail Hg has been significantly correlated with finfish and shellfish intake [119], 
facilitating analysis of the toenail-based studies in quantitative risk assessment. Recent 
experimental research has also strengthened the basis for MeHg’s pro-oxidant MOA on the 
cardiovascular system, increasing ROS and depressing nitric oxide availability [120]. Three 
additional studies have been published since the Stern review supporting an association 
between MeHg and measures of increased blood pressure [121–123]. The implications for 
cardiovascular risk of MeHg’s observed effects on heart rate variability, which seem 
reversible, remain unclear.
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Numerous epidemiologic investigations have shown essential omega-3 fatty acids in seafood 
to be protective of cardiovascular function in both healthy and high-risk populations [110]. 
Mozaffarian and Rimm reviewed the published evidence for both beneficial and adverse 
effects of seafood, and concluded that modest seafood and/or fish oil consumption decreased 
the relative risk of mortality from coronary heart disease by 25% or more [124]. These 
authors also pooled five large studies examining association of MeHg with coronary heart 
disease and found results were inconclusive. However, it should be noted that the two studies 
in this pooled analysis which did not find associations included women. The authors 
conclude that the key public health question of interest may be whether intake of MeHg 
decreases the heart-protective effects of seafood. Seafood species vary in their essential fatty 
acid and MeHg content (e.g., most salmon is high in essential fatty acids and low in MeHg, 
while most swordfish is low in essential fatty acids and high MeHg). Several computer 
models have been developed that can help both policy-makers and seafood consumers 
evaluate the net risks and benefits of seafood consumption on a fish-species specific basis, 
considering omega-3 fatty acid and MeHg content [125–127].
In sum, the epidemiologic evidence base for MeHg’s CVD effects in men has strengthened 
substantially since the NRC report and establishment of the RfD. The epidemiologic base 
(Table 7) is beginning to approach the strength of the base for developmental neurotoxicity 
at the time of the NRC review in 2000 (Table 5). Mechanistic support has also strengthened, 
and measurement concerns related to biomarkers may be more readily addressed. The EPA 
defines as the basis for the critical effect for establishing RfDs “the first adverse effect, or its 
known precursor that occurs to the most sensitive species as the dose rate of an agent 
increases” [46]. The range of 2 ppm mercury in hair may be approximately the 90th 
percentile for men in the US [107], and is near the median for men in high seafood-
consuming countries like Japan [128]. This suggests a large population worldwide may be at 
risk, or at least may not be fully reaping the heart-protective benefits of seafood. It is now 
worth considering whether the Finnish, EU and American studies of MI and other CVD 
outcome risks in men provide sufficient basis for quantitative risk assessment of the 
cardiovascular health effects of MeHg for adult males. Risk characterization should employ 
dose-response modeling and risk-based characterization.
Methylmercury Case Study Conclusions
The MeHg case study reiterates that the “acceptable” level of risk targeted for a chemical 
and health endpoint is a matter of environmental public health policy. Given the erroneous 
assumption that the RfD represents negligible lifetime risk (similar to a 1 in 1,000,000 risk 
for carcinogens), and the estimation that risk level for MeHg at the current RfD is 5 in 1,000 
[52], outputs of NRC-recommended unified dose-response modeling approaches and use of 
risk-specific doses will require explicit policy decisions to determine acceptable levels of 
risk for non-cancer endpoints such as developmental neurotoxicity and cardiovascular 
effects from MeHg.
The use of RfDs as “bright lines” can be misleading for risk management. This case study 
demonstrates how the use of epidemiologic studies can be used to forego assumptions of 
thresholds in order to establish dose-response relationships and how cross-sectional data can 
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inform probabilistic characterizations of population risk, contributing to this goal. A better 
understanding of inter-individual variability will be important in both confirming the 
modeling approach as well as estimating population risk under the new framework. With a 
strong epidemiologic base, ubiquitous exposures and irreversible effects, MeHg will be a 
key candidate for improved understanding of interindividual variability that leads into risk-
specific dose characterizations.
The epidemiologic base has now evolved on cardiovascular disease endpoints in men, and 
suggests risk at doses well below the current point of departure for the developmental 
neurotoxicity. This demonstrates the importance of following up on early epidemiologic 
signals.
COMMON ISSUES AND LESSONS LEARNED FROM CASE STUDIES
In the DBP case study, we examined the rationale and various methods for using 
epidemiologic data in RfD derivation. In the case of MeHg, we assessed the developments in 
the epidemiologic and other scientific literature that show a way forward towards the unified 
dose-response assessment process described in the Science and Decisions report [7]. The 
case studies point to several overarching risk assessment issues: how to evaluate and 
incorporate multiple endpoints in risk assessment; the need for consistent guidelines for data 
sufficiency; and the implications of the unified dose-response and development of risk-
specific doses for non-cancer endpoints. The case studies also present a common lesson 
about the incremental nature of epidemiologic research and its utility for risk assessment.
Multiple Endpoints
The existence of multiple health effects from a particular chemical exposure has been 
addressed in risk assessment by the selection of a critical effect. Critical effects are defined 
as “the first effect, or its known precursor, that occurs in the most sensitive species as the 
dose rate of an agent “increases” [46]. Risk management decisions based on critical effects 
are assumed to be protective of the other effects. In the case of DBP, syndromes -- and 
multiple effects within same syndrome -- affect different populations. If various effects are 
observed at roughly the same dose, the RfD (or RfC) set for the critical effect should be 
protective of all populations. MeHg illustrates another case, that of multiple endpoints and 
different susceptible populations. In this situation, additional analysis may be necessary to 
ensure that the original critical effect (i.e., developmental neurotoxicity) and subsequent risk 
management is adequately protective of populations susceptible to other effects observed 
(e.g., cardiovascular outcomes in adult males).
Weight of Evidence Evaluations, Data Sufficiency, and Data Combination
The case study examples explored questions related to utility of existing data for the purpose 
of hazard identification and dose-response assessment. The DBP case illustrated the need for 
consistent guidelines across all health effects, endpoints and outcomes. Because DBP is 
capable of eliciting developmental and reproductive effects, different risk assessment 
guidelines were applicable to evaluation of these data. Within those guidelines were 
inconsistencies in data sufficiency criteria, particularly as it relates to the certainty of the 
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epidemiologic evidence. In the case of MeHg, at issue is evaluating the quality of evidence 
for a new health endpoint -- in this case cardiovascular outcomes such as increased risk of 
myocardial infarction -- and in determining when there is enough evidence of sufficiently 
high quality to act on a new endpoint.
Use of Epidemiologic Data to Determine Quantitative Dose-Response Relationships
Epidemiologic data reported as RRs or ORs provide opportunities to move toward a 
noncancer quantitative dose-response as recommended by the NAS. The DBP case study 
illustrated how different study results could be interpreted and demonstrated how 
epidemiologic data provided a more scientifically accurate POD. As exemplified in the 
MeHg case study, epidemiologic data provide dose-response information that can be used to 
establish such relationships, which in turn can be used in developing risk-specific doses as 
well as in improving risk communication and in undertaking cost-benefit analysis.
Defining Acceptable Risk for Noncancer Effects—The RfD is currently defined as 
the dose unlikely to result in appreciable adverse health effects over a lifetime [46]. A 
challenge for developing risk-specific doses within the unified dose-response process is 
defining acceptable levels of increased risk for noncancer outcomes. The target range of 
acceptable increased risk for cancer is 1 in 10,000 to 1 in 1,000,000 [80]. No such guideline 
exists for noncancer health effects. Such a guideline will be needed to provide a context for 
risk-specific doses.
It should be noted that use of epidemiologic data in dose-response estimation usually 
obviates the need for interspecies and subchronic-to-chronic adjustment factors (more 
commonly and somewhat misleadingly referred to as uncertainty factors). Accordingly, a 
POD derived using benchmark dose modeling will correspond to the predetermined 
benchmark response, placing it in the range of 1% to 10% response. In the case of human 
data, use of the remaining adjustment factors (database deficiency, interindividual variability, 
and LOAEL-to-NOAEL), typically result in an adjustment downward by a factor of 10 to 
100 (though rarely more than 10), ultimately yielding a level of risk between 1 in 10,000 and 
1 in 100. Such a risk range is in contrast with the range considered to be de minimis used to 
guide risk management and decision-making in the context of carcinogen risk assessment. 
Efforts to develop guidelines for setting risk management objectives for noncancer endpoints 
would be first step towards reconciling these differences in target risks.
Use of Epidemiologic Data to Improve Estimates of Interhuman Variability
Quantification of variability in sensitivity to specific health outcomes among similarly 
exposed people will be needed to contribute to development of risk-specific doses. While 
epidemiologic studies have begun to test for effect modification that may shed light on this 
variability [112], additional work is needed both to mine existing data sources and develop 
new research.
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Lesson Learned: Why Epidemiologic Data Provide Critical Information for Risk 
Assessment
The development of the epidemiologic datasets for DBP and MeHg highlights facets of 
epidemiologic research that argue for its use in risk assessment. Health effect signals from 
epidemiologic research are important because there are many factors that can obscure results 
by biasing observed associations towards the null; therefore, when associations are found in 
the face of these challenges, attention is warranted. Further, in both of the cases reviewed, a 
pattern was evident -- early studies of health effect signals were replicated later, particularly 
for effects which were concordant with animal studies. Therefore, early use of 
epidemiologic studies is both prudent and scientifically justified.
DISCUSSION AND RECOMMENDATIONS
As efforts to expand the characterization of the impacts of chemical exposures on human 
health continue [129], it is increasingly apparent that reliance on our current decision-
making process, especially as supported by historic methods of dose-response estimation, is 
untenable. We present two case studies that examine how animal and human evidence were 
incorporated into risk assessments. In both cases, we propose that epidemiologic data could 
be used in place of animal data, or used differently, to take full advantage of the state of 
knowledge. Based on case studies results and the discussion of new directions in 
environmental public health science, we provide recommendations for enhancing the use of 
epidemiology in risk assessment (Table 8).
Recommendations for Epidemiology
Recommendation: Epidemiologic investigations should strive to employ 
markers of exposure and upstream effect to enhance study sensitivity.—
Epidemiologists can improve the utility of their research through lessons from mechanistic 
toxicology. Detection of rare effects and subtle (but meaningful) changes in continuous 
biological parameters is a persistent challenge in the field of epidemiology, compounded by 
difficulties in ascertaining an adequate sample size. In an example provided in a minority 
report accompanying an EPA Science Advisory Board comment on human subjects testing, 
Needleman and Reigert assert that in the case of pesticides, detection of a small effect, such 
as a 1% increase in the rate of a rare neurobehavioral toxicity with a base rate of deficit of 
1%, would require a sample size exceeding 3,000 subjects per group [130], highlighting the 
burden epidemiologists face in ensuring the ability to discern a true effect, as many overt 
diseases are in the 1% or less range of observations (e.g. cancer, birth defects).
The challenges of detecting rare and difficult-to-measure effects may be in part addressed by 
development of toxicity pathways and establishment of markers of early biological 
perturbation. Utilization of these upstream effect measures in epidemiologic investigation 
increases sensitivity in outcome measurement; such refinements in outcome assessment 
techniques are likely to reduce the number of subjects needed to achieve sufficient power to 
see an effect. Changes in testosterone levels resulting from DBP exposure would be an 
example of a more sensitive and upstream event.
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Markers of upstream effect also hold promise for reducing misclassification. 
Epidemiologists are often forced to rely upon non-objective and surrogate exposure 
measures, which suffer from numerous biases that may influence estimation of dose-
response relationships. These misclassifications, when not differential, tend to dampen 
estimates of association, whereas when differential, may bias effect estimates in manner that 
is unpredictable in magnitude and direction. The potential impacts of biases stemming from 
exposure measurement errors are rarely investigated [131]. Reliance on frank effects as 
outcomes can intensify the likelihood that persons who have progressed along the 
toxicodynamic continuum but have not yet reached a clinically apparent disease state will be 
misclassified as not having the disease. Such misclassification can be differential and may 
result in the weakening of effect estimates, ultimately resulting in the inability to observe an 
effect.
Numerous changes in the landscape of environmental public health science may serve to 
enhance the ability of epidemiologists to build the case for relationships between exposures 
and subtle or rare events. As the knowledge base regarding toxicity pathways expands, it 
will become increasingly possible to examine upstream biological changes as outcomes in 
epidemiologic studies. The elucidation of these toxicity pathways may help identify new and 
previously unrecognized early biomarkers of toxicodynamic progression towards overt 
disease. The growing recognition of the value of biomonitoring data in epidemiologic 
investigations also holds promise for reducing misclassification by providing objective 
measures of exposure and outcome. As biomarker data for exposure, outcome and 
susceptibility are increasingly generated, epidemiology will play a prominent role in 
developing an understanding of toxicodynamic progression as a function of chemical 
exposure.
Recommendation: Develop a consistent format for epidemiologic results 
reporting to facilitate cross-study comparisons and data combination 
methods (such as meta-analysis).—Measures of exposure and effects estimates with 
associated variability (preferably in the form of standard errors) are the essential data 
elements to be evaluated when assembling a data set for risk assessment. In rare instances, 
access to primary data may be requested. Access to primary data allows evaluation of 
various types of measurement error in exposure assessment (and subsequent 
misclassification or bias) or may be combined in a dose or exposure response analysis using 
a meta-analysis or other data combination approach [131].
Recommendation: Susceptibility factors should be analyzed as effect 
modifiers.—Beyond the advantages afforded by improvement in exposure characterization, 
recognition of host factors that influence toxicity are also of key importance. More accurate 
quantification of susceptibility due to genetic differences, age and gender, diet, health status 
and socioeconomic status will inform probability of distributions of uncertainty and 
variability. One important strategy, where possible, is testing whether these specific 
susceptibility factors modify the relationship between intake of a chemical and its internal 
dose as measured in some body tissue (i.e., effect modification in toxicokinetic pathways), 
and between intake or internal dose and measures of early or later effect (i.e., modifications 
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in toxicodynamic pathways). Often, these factors are simply adjusted for as potential 
confounders [112]. For chemicals with validated biomarkers of dose and early effect, 
NHANES and other large cross-sectional surveys can be used to estimate variability 
distributions for factors known to influence susceptibility.
Recommendation: Conduct joint analyses when data on multiple related 
exposures or outcomes are available.—Although epidemiologic data have the 
potential to inform pressing health risk questions related to multiple exposures and 
outcomes, most analytical epidemiologic studies try to isolate a specific causal or 
explanatory factor for a well-defined outcome. For outcomes thought to originate from a 
common biological perturbation, epidemiologic studies that examine associations between 
exposures and grouped outcomes may be informative in the risk assessment process. 
Similarly, for exposure to multiple agents thought to act on common targets, efforts to assess 
the joint action of the combined exposures would be highly relevant for risk assessments. As 
evidence of MeHg’s ability to elicit effects in multiple organ systems continues to accrue, it 
becomes increasingly clear that the current risk practice of selecting a single critical effect 
will underestimate MeHg’s total impact. Joint or combined analyses will provide better 
characterizations of risk.
Recommendations for Risk Assessment
Recommendation: Use the dose-response information from epidemiologic 
studies of noncancer effects as the basis for developing quantitative risk 
estimates.—Critical changes in how risk assessors use epidemiologic data, coupled with 
reconsideration of some of the fundamental methodologies in how dose-response data are 
employed in assessments are warranted. The unified approach for cancer and noncancer dose 
response assessment presented by the NRC [7] promotes the movement away from the 
default threshold-based hazard metric embodied by the RfD and RfC and allows for a 
spectrum of considerations, including factors that predict host susceptibility, among others, 
to influence the selection of dose-response model. This evidence and data-driven approach 
to model selection allows for a more holistic incorporation of available data, extending 
beyond the current method of selecting a single dataset and setting an artificial bright-line 
and moving towards a risk-specific dose that is better suited for evaluations of risk-tradeoffs 
and benefit-cost analyses [7]. Such an approach will allow risk assessors to employ 
estimates of slope for chemicals as the default approach on both individual and population 
bases and attempts to provide a quantitative description of risk across numerous doses with 
consideration of changes in slope across dose when mechanistic information suggests 
differences from the observed slope at high dose to the slope at low dose (in the range of 
environmental exposures). The risk-specific dose as proposed by NRC provides a risk metric 
for noncancer effects consistent with the existing approach for cancer risk estimates [132–
134]. It is recognized that some estimates of slope derived from the observed range 
(especially those derived from evaluations of occupational exposures) may not reflect those 
in the lower, environmentally-relevant range; accordingly, steps should be taken to account 
for heterogeneity in response in the low dose range across the population [7]. 
Characterization of risks corresponding to a range of doses, combined with the NRC 
recommendation to combine risks for chemicals that elicit similar health effects or act on the 
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same organ system, allows risk assessors to more fully consider the relevance of multiple 
exposures in the decision-making process.
Well-researched examples from the epidemiologic literature (particulate matter, ozone, lead, 
secondhand or environmental tobacco smoke and radon) reinforce the case and provide 
examples for updating dose-response assessment and procedures for extrapolation of dose-
response to low doses. Population studies have found no threshold for particulate matter and 
all-cause and cardio-respiratory mortality [135], ozone and mortality [136], lead and 
cognitive function [137], second hand tobacco smoke and radon and lung cancer [138–140], 
consistent with the NRC recommendations.
Recommendation: Risk assessments should move toward a more systematic 
and transparent evaluation of the existing evidence.—Evidence-based medicine 
and public health rely on systematic literature review and evidence synthesis methods [141, 
142]. A valuable attribute of these methods is that a transparent literature search strategy 
assures that all relevant research has been gathered for review. Sometimes proprietary data 
are used in risk assessments. Incorporating data from a systematic literature review would 
expand the dataset for the risk assessment and also balance proprietary data with information 
from the broader literature.
Systematic reviews use well-defined literature search and statistical evaluation techniques to 
appraise study validity and summarize research on specific health effects. Systematic review 
has been defined as “the application of scientific strategies, in ways that limit bias, to the 
assembly, critical appraisal, and synthesis of all relevant studies” [143]. The statistical tools 
of meta-analysis, which capture an effect size from various studies, are often but not always 
applied to a systematic review. Systematic reviews for intervention-based clinical medicine 
review randomized clinical trials (RCTs) as the “gold standard.” However, environmental 
epidemiology relies mainly on observational studies such as cohort and case-control studies, 
due to ethical and other issues related to designing experimental studies to examine chemical 
health effects in populations. The Cochrane Collaboration and other organizations have 
developed transparent guidelines for systematic reviews of intervention-based RCTs in 
developing the underpinnings of evidence-based medicine [142]. However, these 
organizations are now beginning to also look at observational studies. Key concerns with 
performing systematic review of observational studies are heterogeneity of design and 
inherent biases and confounding, need to search extensively and demonstrate reproducibility 
due to tendency of observational studies to overestimate exposure effect [144]. One new 
method that may be particularly useful for risk assessment is the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) approach, which is 
a system for grading, or rating, evidence in the health field. In using a weight of evidence 
approach, risk analysts and policy makers are influenced by both the conclusion of an 
assessment but also their confidence in the estimates. The GRADE system is a systematic 
method to rank confidence in the summarized evidence [145]. An approach that values the 
supporting toxicological evidence is important for this approach, as animal evidence is not 
currently part of the GRADE system, and toxicological evidence has clearly been identified 
(e.g. cancer guidelines) as critical supporting information. Work is ongoing in this area 
(Sutton, personal communication).
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Recommendation: EPA should develop a set of data sufficiency and 
evaluation criteria for epidemiologic data to be applied uniformly across 
different types of endpoints (cancer and noncancer).—The 2005 Guidelines for 
Carcinogen Risk Assessment discussion of data sufficiency for each descriptor provides a 
useful foundation for this effort; a summary of this is provided in Table 9. The review of the 
EPA’s developmental, reproductive toxicity and carcinogen risk assessment guidance 
documents in the DBP case example found that differing standards of data sufficiency apply 
to epidemiologic data evaluations for risk assessments of these endpoints. Differing 
guidance presented a challenge for assessing DBP and will be a challenge for other 
compounds where there is evidence for multiple effects stemming from a single biological 
perturbation or exposure. Similarly, as methods for cumulative risk assessments develop and 
move towards addressing multiple endpoints in addition to multiple stressors, the existing 
endpoint-specific guidance will impede rather than foster those more comprehensive 
assessments.
Recommendation: EPA’s definition of “critical effect” used in developing 
toxicity values for risk assessment should be consistent with its definition of 
“adverse effect” and include early upstream events.—There is a growing 
consensus in the risk assessment community that the definition of critical endpoint needs to 
be refined to reflect our rapidly advancing understanding of adversity [50]. Further, we have 
identified clear inconsistencies between the EPA IRIS definitions for critical and adverse 
effects. As more attention is focused on elucidation of toxicity pathways [4] and our ability 
to detect early biological perturbations improves through advances in biomonitoring and in 
‘omics technologies, it is incumbent upon risk assessors to acknowledge subtle changes 
early along the toxicodynamic pathway that are indicative of increased potential for 
downstream effects [50]. As such, the selection of clinically-overt health effects as critical 
endpoints upon which dose-response assessments are based is an outdated practice in need 
of modernizing. A move towards recognition of upstream, subclinical effects in risk 
assessments shows promise for recognition of the potential for shared toxicity pathways 
across chemicals. As stated in the EPA IRIS definition of “adverse effect”, such an 
acknowledgement that these subtle biochemical changes may themselves affect the 
performance of an organism or reduce the capacity for response to additional environmental 
challenges would well serve risk assessors to meet newer types of dose-response data 
generated as the field of environmental epidemiology moves forward.
Recommendation: Risk assessors should reframe the concept of critical 
effect to move beyond determination of a single adverse endpoint to consider 
syndromes and groups of adverse endpoints that stem from the same initial 
biological perturbation.—In regards to selection of critical endpoints, it is relevant that 
risk assessors evaluate the evidence in support of multiple adverse outcomes stemming from 
the same initial biological perturbation. Given interindividual variability in numerous host 
factors, including metabolic profiles, co-exposures and co-morbidities, it is possible that 
variation may exist in the manifestation of adverse outcomes in response to a chemical 
challenge; phthalate exposures and testicular dysgenesis syndrome and the collection of 
motor skill, cognitive and behavioral outcomes resulting from lead exposures are two 
Nachman et al. Page 32
Open Epidemiol J. Author manuscript; available in PMC 2019 July 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
prominent examples of this phenomenon [61, 64, 146]. Ideally, the relationships between 
exposures and combinations of related endpoints would be addressed in epidemiologic 
studies, though this is frequently not the case. Accordingly, the field of risk assessment 
would be well served by developing procedures for evaluating evidence for co-occurrence of 
multiple adverse outcomes as a critical endpoint for toxicity value derivation.
Historically, when faced with data from multiple epidemiologic and experimental animal 
studies that evaluate the relationship between exposures and different health outcomes, risk 
assessors seek to identify the most sensitive adverse endpoint (derived from a single study) 
for quantitative estimation of a point of departure. The shortcoming of this approach is that, 
in the instance of multiple, exposure-related outcomes, characterization of risk based on a 
POD derived from one of many outcomes may neglect the true population risk of developing 
any number of adverse conditions relevant to the exposure of interest. Increased recognition 
of syndromic morbidity in the epidemiologic community and improvements in endpoint 
selection in epidemiologic studies will aid risk assessors in critical endpoint selection. 
However, as risk assessors are often reliant on data from studies not recently conducted, 
awareness of the potential for related sequelae from exposures to the same agent should 
weigh heavily when attempting POD derivation.
Trans-Disciplinary Recommendation
Recommendation: Create opportunities for cross-disciplinary training and 
collaboration between epidemiologists and toxicologists. Epidemiologists 
should be provided with training in regulatory risk assessment.—Risk 
assessment aims to inform the decision-making process in the environmental policy arena. 
An understanding of the risk assessment process will equip epidemiologists with the basis 
for ensuring that the results of their work are translatable into a format that is amenable into 
the hazard identification and dose-response characterization steps of risk assessments.
Studies in experimental animals have largely provided the basis for derivation of toxicity 
values in IRIS toxicological assessments [56]. While the explanation for this may rely on 
available evidence in the literature, it may be partially explained by the possibility that the 
expertise of the IRIS team is more weighted towards toxicology. An increased recognition of 
the role of epidemiologists in the development of toxicity assessments could enhance the 
ability of IRIS to take full advantage of a chemical’s available health effect database. This 
must be combined with a concerted effort by EPA to bring in more epidemiologists, as the 
comparatively fewer epidemiologists at the agency contribute to epidemiologic data being 
undervalued.
CONCLUSIONS
Epidemiology is essential to our understanding of the role of environmental exposures in 
human disease. After all, it is only by studying the human population that we will 
understand the complex interactions of the environment, social factors, heredity, and 
behavior that determine individual and population health. This paper has explored the role of 
epidemiologic data in supporting and shaping chemical risk assessment and related risk 
management policies. Our examination of current chemical risk guidelines indicates the 
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dominance of animal toxicology studies in chemical risk assessments and a disconnect 
between available epidemiologic data and the needs of risk decision makers. However, 
advances in exposure science, biomarkers of internal dose and early effect, understanding of 
population variability in susceptibility, and population health surveillance combine to 
provide an unprecedented opportunity to revitalize the role of epidemiology.
Our current biomonitoring efforts document widespread exposure to a host of chemicals for 
which toxicity information is lacking. Development of timely traditional chemical-specific 
risk assessments for the tens of thousands of potential environmental pollutants has proven 
to be an exercise in futility. In addition, it remains difficult if not impossible to demonstrate 
the public health benefits of many chemical risk management efforts. We can make advances 
now by better integrating existing epidemiologic studies with our current understanding of 
toxicodynamic processes from in vitro, in vivo, and ultimately in silico experiments. As 
biomonitoring advances our understanding of population exposures, and biomarkers expand 
our understanding of susceptibility and early biological effects, it is time to develop a new, 
trans-disciplinary lens through which we can examine environment and health. Improving 
risk assessment will require multidisciplinary involvement from the earliest problem 
formulation stage through the characterization and management of risks. Epidemiologists 
and other environmental health disciplines with cross-training in epidemiology can shape 
new approaches to addressing cumulative population risks, prioritizing chemicals for 
evaluation, and addressing the scientific needs of decision makers.
To be sure, many challenges remain in advancing the role of epidemiology in chemical risk 
assessment. Those in search of bright lines and thresholds will continue to be frustrated by 
the limits of human studies. However, bolstered by advanced tools and improved study 
designs, epidemiology may hold the key to shedding new light on the recognition, 
prevention, and management of chemical risks.
ABBREVIATIONS
AGD Anogenital distance
AGI Anogenital index
BMD Benchmark dose
BMDL Lower confidence limit on the BMD
CDC Centers for Disease Control and Prevention
CNS Central nervous system
CSF Cancer slope factor
CVD Cardiovascular disease
DBP Di-butyl phthalate
DNA Deoxyribonucleic acid
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DWUR Drinking water unit risk
EPA United States Environmental Protection Agency
GGT Gamma glutamyltransferase
GRADE Grading of Recommendations Assessment, Development and 
Evaluation
Hg Mercury
iHg Inorganic mercury
insl3 Insulin-like growth factor 3
IRIS EPA Integrated Risk Information System
IUR Inhalation unit risk
LH Lutenizing hormone
LIN Sperm linearity
LOAEL Lowest observed adverse effect level
MBP Mono-butyl phthalate
MBzP Mono-benzyl phthalate
MeHg Methylmercury
MEP Mono-ethyl phthalate
MI Myocardial infarction
MiBP Mono-isobutyl phthalate
MiNP Mono-isononyl phthalate
MOA Mode of action
MR Lymphatic cholinergic muscarinic receptor
NCS National Children’s Study
NHANES National Health and Nutrition Examination Survey
NHEXAS National Human Exposure Assessment Survey
NOAEL No observed adverse effect level
NRC National Research Council
NRDC National Resources Defense Council
OR Odds ratio
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PD Pharmacodynamic
PK Pharmacokinetic
POD Point of departure
PPARα Peroxisome proliferator-activated receptor-α
ppb Parts per billion
ppm Parts per million
RCT Randomized clinical trial
RfC Reference concentration
RfD Reference dose
ROS Reactive oxygen species
RR Relative risk
SES Socioeconomic status
SHBG Sex-hormone binding globulin
T4 Thyroxine
TR Toxicological Review
UF Uncertainty factor
VCL Sperm curvilinear velocity
VSL Sperm straight-line velocity
AMI Acute myocardial infarction
BP Blood pressure
CHD Chronic heart disease
CVD Cardiovascular disease
EU European Union
EURAMIC European Union Acute Myocardial Infarction and Cancer study
g Gram
HRV Heart rate variability
IMT Intima media thickness
IPCS International Programme on Chemical Safety
KIHD Kuopio Ischemic Heart Disease study
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L Liter
Nmol Nanomol
PTWI Provisional tolerable weekly intake
PUFA Polyunsaturated fatty acid
ug Microgram
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Fig. (1). 
IRIS toxicity assessments (or updates) using human data for toxicity value derivation, 5-year 
increments.
*Displayed numbers represent number of assessments/updates where human data supported 
critical effect during 5-year increment, the total number of assessments/updates completed 
during 5-year increment, and in parentheses, the percentage of assessments/updates where 
human data supported the critical effect.
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